MedTech vulnerability scanning shifts costs to hospitals

AdvancedUNO
24 Jun, 2026
MedTech vulnerability scanning shifts costs to hospitals

9 min read

The Balance Sheet of Connected Risk

  • The Definition: MedTech vulnerability scanning is the process of identifying, cataloging, and analyzing security flaws in connected clinical hardware, ranging from bedside infusion pumps to multi-million-dollar imaging suites.
  • The Operational Reality: Device manufacturers capture the high margins of equipment sales and software licensing, while clinical engineering teams at hospitals bear the labor-intensive costs of manual risk validation and patching.
  • The Failure Mode: Standard automated IT scanning tools frequently crash legacy clinical systems, forcing security leaders to choose between dangerous operational blind spots and labor-intensive manual sandboxing.

Who pays when a legacy infusion pump fails a security scan?

When a security scan flags a critical vulnerability on a live infusion pump, the hospital CISO must choose between clinical downtime and network exposure.

This is not a hypothetical dilemma. It is a daily operational friction point inside modern clinical networks, where the rapid expansion of connected clinical technology has far outpaced the systems designed to secure it. According to projections from Deloitte, connected devices are expected to make up 68% of all medical hardware, turning clinical units into highly complex, distributed IT networks. Yet, the economics of securing these devices remain heavily asymmetric, leaving healthcare delivery organizations to absorb the costs of a systemic security deficit.

To understand the depth of this challenge, one must look at the sheer volume of legacy hardware currently operating in patient care areas. A study by Palo Alto Networks and Cynerio analyzed 200,000 infusion pumps across healthcare organizations and found that 75% of these devices possessed known security flaws. More troubling still, 52% of all scanned pumps were susceptible to two specific vulnerabilities disclosed in 2019, one classified as critical and the other as high severity. Because the average operational lifespan of an infusion pump ranges from eight to ten years, hospitals are routinely forced to run legacy hardware that was never designed to defend against modern network exploits.

This long operational tail creates a financial mismatch. Original equipment manufacturers sell clinical hardware with lucrative, multi-year service contracts, capturing the economic value upfront. When critical vulnerabilities are later disclosed—such as those affecting Becton Dickinson Alaris systems first flagged in 2017, 2019, and 2020—the manufacturer may release a software update, but the logistical and financial burden of deploying that patch across thousands of active clinical units falls entirely on the hospital's clinical engineering team. The manufacturer remains insulated from the operational friction, while the hospital quietly absorbs the labor costs and the liability of delayed remediation.

The friction of passive network sniffing versus active lab validation

To manage this risk, hospital security teams generally rely on two distinct operational methodologies, each carrying its own balance sheet of costs, limitations, and friction. The first approach is passive network monitoring, which uses network taps or switch port analyzer ports to capture and analyze clinical traffic. Specialized security platforms, such as those from Claroty, Armis, or Ordr, parse clinical protocols like DICOM and HL7 to identify connected medical devices based on their network signatures, matching them against known vulnerability databases without interacting with the physical hardware.

Passive monitoring is like a building security system that flags every open window from a street-level camera. It tells you a gap exists, but it cannot verify if the window is barred from the inside or if an intruder can actually climb through it.

The second approach is active, lab-based validation, where clinical engineers and security analysts test physical hardware in a controlled sandbox environment. This model was embraced by TRIMEDX and Indiana University Health, who collaborated to build a dedicated medical device security lab to test vulnerabilities during the product procurement and development processes. Similarly, Deloitte India launched its 4,500-square-foot ConnectSafe facility to simulate real-world cyber threats across connected MedTech systems without impacting live hospital operations. This active methodology allows organizations to verify whether a vulnerability is truly exploitable in their specific network configuration before committing engineering hours to patch it.

The noise machine of passive clinical alert pipelines

The primary point of confusion for healthcare IT teams is why passive scanning platforms generate thousands of critical alerts that cannot be acted upon. Because these tools rely on signature matching, they flag vulnerabilities based on the device's declared operating system or firmware version, regardless of whether the vulnerable component is actually active or reachable on the network. For example, when the MDhex-Ray vulnerability was disclosed, impacting dozens of GE medical imaging devices including CT scanners, MRI machines, and ultrasound systems, passive scanners across the country flagged thousands of devices as highly vulnerable.

The vulnerability could theoretically allow an attacker to gain remote access comparable to a service user, potentially exposing sensitive patient data or taking control of the machine. However, actually exploiting this vulnerability requires specific network access and configuration states that passive scanners cannot verify. Hospital security teams are left with massive spreadsheets of critical alerts but no clear mechanism to determine which devices present a real, immediate threat to patient care and which are protected by existing network segmentations.

"An unverified vulnerability alert is not an actionable security task; it is an administrative debt assignment that the hospital must pay to resolve."

Calculating the hidden operational costs of a clinical patch cycle

To appreciate why active lab validation is gaining traction despite its high capital requirements, we must examine the actual steps required to remediate a critical vulnerability across a regional health system. Consider a representative hospital network operating 1,200 connected infusion pumps running legacy firmware with a known CVSS 9.8 remote code execution vulnerability.

Vulnerability Density in Scanned Infusion Pumps
Pumps with Cyber Flaws75 %Susceptible to 2019 Flaws52 %

Figures compiled from the sources cited below.

  1. Vulnerability Triage and Lab Replication: Rather than risking a live network disruption, security analysts pull a representative pump from clinical rotation into the lab. Using simulated traffic generators, they attempt to replicate the exploit. This step verifies whether the hospital's existing virtual local area network segmentations and firewall rules are sufficient to block the attack vector without requiring a firmware update.
  2. Manual Firmware Deployment: If the vulnerability is indeed exploitable and network mitigations are insufficient, clinical engineers must physically locate all 1,200 pumps distributed across multiple hospital wings. Because medical devices rarely support automated, over-the-air firmware updates, engineers must take each pump out of service, connect it physically to a service laptop, and manually apply the software update provided by the manufacturer.
  3. Post-Patch Validation and Recalibration: Once the patch is applied, the device must undergo standard biomedical calibration and safety testing to ensure the software update did not alter the pump's delivery algorithms or sensor sensitivity. Only after this validation is completed can the device be sanitized and returned to clinical inventory.

A single firmware update across a distributed fleet can consume hundreds of clinical engineering hours, quietly draining the hospital's operating margin while the device manufacturer remains financially insulated.

The stakes of failing to execute this process are rising. In March 2026, a destructive wiper attack claimed by Iran-backed hackers targeted the MedTech firm Stryker, demonstrating that cyber adversaries are actively targeting the supply chains and operational technologies of healthcare systems. If a similar wiper attack were to traverse a hospital's internal network and compromise unpatched clinical devices, the cost of operational downtime would quickly dwarf the labor costs of manual patching. As noted by security researchers during the GE MDhex-Ray disclosure, the downtime of critical imaging systems is incredibly expensive for hospitals, both in lost revenue and in delayed clinical decision-making for critical patients.

Where passive scanning actually holds up

  • Passive scanning is a waste of time because it cannot patch devices: While passive monitoring cannot automatically remediate a flaw, it remains the only viable method for maintaining an accurate, real-time asset inventory across a large healthcare system. Without it, clinical engineering teams would have no way of knowing how many legacy systems are active on their networks at any given moment.
  • Active lab testing is always superior to passive monitoring: Active lab testing provides deep, highly accurate risk validation, but it is financially and operationally impossible to scale for every device. A hospital system cannot build a physical sandbox for every firmware variation of every patient monitor, thermometer, and lab analyzer in its inventory; passive scanning must serve as the initial triage filter.
  • Device manufacturers will eventually secure all legacy devices: Manufacturers face little financial incentive to write, validate, and distribute security patches for hardware that has passed its end-of-sale date. The regulatory requirements enforced by the FDA largely focus on pre-market security controls for new devices, leaving hospitals to manage the security lifecycle of legacy equipment on their own.

Rule of Thumb: If your organization lacks the budget to employ dedicated clinical engineers for manual device validation, investing in active lab testing facilities is a sunk cost; you are better off using passive monitoring to enforce aggressive network segmentation at the switch level.

Frequently Asked Questions

What happens to our clinical operations if an active vulnerability scan accidentally crashes a legacy GE MRI machine during a patient scan?

An active vulnerability scan that sends aggressive ping sweeps or Nessus probes to a legacy medical device can easily overwhelm its limited network interface card, causing the device to freeze, reboot, or drop its connection to the electronic health record. If this occurs during a live patient scan, the procedure must be immediately aborted, potentially requiring the patient to be rescheduled, exposing them to unnecessary radiation or contrast dye, and costing the hospital thousands of dollars in lost scanner utilization. This is why active scanning should never be performed on live clinical networks, and security teams must rely on passive monitoring or isolated lab testing instead.

Why can't we just use automated IT patch management systems like Microsoft Intune or Tanium to secure our connected medical device fleet?

Connected medical devices run on specialized, embedded operating systems—such as VxWorks, QNX, or custom Linux distributions—that are entirely incompatible with standard enterprise patch management agents. Furthermore, medical devices are closed, proprietary systems; installing third-party software agents would void the manufacturer's warranty and violate the device's FDA cleared specifications. Any modification to the device's software must be developed, validated, and signed by the original equipment manufacturer, meaning hospitals cannot deploy patches independently of the vendor's release cycle.

If a manufacturer like Becton Dickinson releases a patch for an Alaris pump, who bears the legal and financial liability if we delay deployment due to staffing shortages?

Once a manufacturer releases an official security patch or mitigation strategy, the operational and legal liability for any exploit-related device failure shifts almost entirely to the healthcare delivery organization. Under HIPAA security rules and general tort law, if a hospital fails to apply a known, available patch within a reasonable timeframe and a patient is harmed due to a cyberattack on that device, the hospital can be held liable for negligence. The manufacturer's liability is generally limited to providing the patch, while the hospital must absorb the operational risk and cost of deployment.

The Real Cost of Connected Care: The economic value of MedTech cybersecurity is captured by vendors selling software and manufacturers selling hardware, while the operational friction is absorbed by hospital clinical teams. Ultimately, the choice between passive monitoring and active lab validation depends on your organization's clinical engineering maturity. If you do not have the internal engineering hours to manually validate and deploy patches, active testing labs are an expensive distraction, and your security dollars are better spent on strict network segmentation to isolate vulnerable devices from the broader IT environment.

Related from this blog

Sources

Next Post Previous Post
No Comment
Add Comment
comment url